Obermatt
See Similar Stocks →

Panion & Bf Biotech

TAI:1760 · TW0001760007
PharmaceuticalsSmall

360

84
Medium confidence — indicative
EV / EBIT35
Price / Owner Earnings8
Owner Earnings Yield67
Dividend Yield1
Price/Sales21
EV / Gross Profit31
Price/Book17
Return on Capital94
Cash Return on Capital87
Return on Equity87
EBIT Margin87
Gross Profitability79
Cash Conversion51
Accruals35
Owner Earnings Margin88
Sales growth79
Profit Growth73
Long-Term EPS Growth59
Owner Earnings Growth93
Reinvestment63
Price momentum33
Debt load52
Refinancing14
Debt Payback47
Liquidity84
Analyst ratings1
Expectations trend50
Market mood4
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Panion & Bf Biotech generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTWSE
Employees29
Websitepbf.com.tw
ISINTW0001760007
Last UpdateApr 2, 2026
Index & Theme
Pain ManagementRespiratoryVaccinesInfectious DiseasesNephrologyBiotechnologyPharmaceutical

Description

Analysis

Quality compounder

Panion & Bf Biotech Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 27.0×; owner earnings: the cash an owner could take out each year.

Growth is solid; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
33
2023202420252026

All-time high

51

Mar 2026

All-time low

1

Jan 2025

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
21
26
22
31
Price/Earnings
31
17
33
53
Price/Book
17
17
16
20
Dividend Yield
1
52
57
33
Value (overall)
10
24
28
29

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Panion & Bf Biotech with its peers
Chunghwa Chemical Synthesis & Biotech
TAI:1762
13
CountryTaiwan
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Bora Pharmaceuticals
TAI:6472
27
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Aprogen Biologics
KSC:003060
10
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Wave Life Sciences
NMQ:WVE
20
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ScinoPharm
TAI:1789
25
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
DongKook Pharmaceutical
KOE:086450
93
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →